Life sciences news
-
Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia
Wednesday October 4th 2023
Read more
-
SwiftPharma and Medace sign strategic collaboration agreement for biomanufacturing and purification of promising medicinal proteins.
Wednesday September 27th 2023
Read more
-
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen
Wednesday September 27th 2023
Read more
-
argenx announces positive CHMP opinion for subcutaneous efgartigimod for generalized myasthenia gravis
Friday September 15th 2023
Read more
-
SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV
Friday September 8th 2023
Read more
-
SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure
Friday September 1st 2023
Read more
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Tuesday August 29th 2023
Read more
-
ViroVet achieves groundbreaking results with antiviral drug against BVD
Monday August 28th 2023
Read more
-
Become a flanders.bio member
Your news here?
-
argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy
Monday July 17th 2023
Read more
-
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
Monday July 10th 2023
Read more
-
argenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy
Tuesday June 20th 2023
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
